AGCT1532 - Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Brief description of study
The purpose of this study is to investigate the accelerated BEP in improving the safety and efficacy for patients with intermediate and poor-risk metastatic germ cell tumours. We want to know if accelerated BEP is superior to standard BEP.
We are using study drugs Ifosfamide, Cisplatin, Pegfilgrastim, Etoposide, Bleomycin, MESNA and Filgrastim to determine progression- free survival, adverse events, and health-related quality of life.
Clinical Study Identifier: s22-00117
ClinicalTrials.gov Identifier: NCT02582697
Principal Investigator:
Sharon L Gardner.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.